Overview
- The agreement announced Monday gives Lantheus shareholders $102.50 per share in cash plus non-transferable contingent value rights that could add up to $12 by 2030, bringing total possible consideration to $114.50 per share.
- The transaction will take Nasdaq-listed Lantheus private and is expected to close in the first half of 2027 with funding from a mix of debt and equity provided by Curium and its backer CapVest Partners.
- Analysts described the $102.50 upfront as fair but not generous and noted the premium over recent trading; Lantheus stock rose after the announcement.
- Market watchers warned the deal may face heightened regulatory scrutiny because both firms are major providers in diagnostic radiopharmaceuticals, a fast-growing area used in PET imaging and targeted therapies.
- Lantheus’s lead product Pylarify and Curium’s global manufacturing and theranostics capabilities are central to the rationale for the tie-up, which industry deals suggest will further consolidate the radiopharmaceuticals market and could affect patient access and competition.